This trial is testing whether a drug can help prevent major heart problems in people who have had a heart attack.
- Heart Attack
1 Primary · 2 Secondary · Reporting Duration: Through study completion, estimated at 1-year
Awards & Highlights
2 Treatment Groups
1 of 2
1 of 2
8 Total Participants · 2 Treatment Groups
Primary Treatment: Rivaroxaban · Has Placebo Group · Phase 2 & 3
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many people are the most that can join this clinical trial?
"That is correct. The clinicaltrials.gov website shows that this trial is currently recruiting patients. The trial was posted on April 5th, 2021 and was last updated on May 19th, 2022. The study is looking for 100 patients at 1 location." - Anonymous Online Contributor
Is this research project novel in terms of its design or purpose?
"Rivaroxaban's journey through clinical trials began in 2015 with Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma sponsoring the first study. 2180 patients participated in the first Rivaroxaban trial, which resulted in the drug being approved for Phase 3 clinical trials. As of now, there are 61 active clinical trials for Rivaroxaban taking place in 402 cities and 45 countries." - Anonymous Online Contributor
What indications does Rivaroxaban usually cover?
"Rivaroxaban is most often used as a treatment for venous thromboembolism, but it can also be given to patients suffering from deep vein thrombosis, chronic coronary artery disease, and cerebrovascular accident." - Anonymous Online Contributor
Are patient applications being accepted at this time?
"The clinical trial is currently recruiting participants, with the original posting on 2021-04-05 and the most recent update on 2022-05-19." - Anonymous Online Contributor